Analytical Data
-
Gene name
GNPDA1
- Application
-
Alternative Names
GNPDA1;GNPI;HLN;KIAA0060;Glucosamine-6-phosphate isomerase 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P46926
-
Expression Region
1-289aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MKLIILEHYS QASEWAAKYI RNRIIQFNPG PEKYFTLGLP TGSTPLGCYK KLIEYYKNGD LSFKYVKTFN MDEYVGLPRD HPESYHSFMW NNFFKHIDIH PENTHILDGN AVDLQAECDA FEEKIKAAGG IELFVGGIGP DGHIAFNEPG SSLVSRTRVK TLAMDTILAN ARFFDGELTK VPTMALTVGV GTVMDAREVM ILITGAHKAF ALYKAIEEGV NHMWTVSAFQ QHPRTVFVCD EDATLELKVK TVKYFKGLML VHNKLVDPLY SIKEKETEKS QSSKKPYSD
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GNPDA1 (Glucosamine-6-phosphate isomerase 1) has garnered significant attention in recent years due to its pivotal role in cellular metabolism and potential implications in various diseases. This enzyme catalyzes the isomerization of glucosamine-6-phosphate, playing a crucial part in the hexosamine biosynthetic pathway, which is linked to cellular signaling, growth, and stress responses. Dysregulation of this pathway has been associated with metabolic disorders, including obesity and diabetes, as well as neurodegenerative diseases like Alzheimer's. Emerging research indicates that GNPDA1 may also influence the development of certain cancers, making it a promising target for therapeutic intervention. The recombinant expression of GNPDA1 allows for a deeper understanding of its functional mechanisms and provides a valuable tool for drug discovery. By studying the enzyme's structure and activity, researchers aim to identify inhibitors that can modulate its function in disease contexts. Furthermore, insights from such studies could pave the way for novel strategies in metabolic disease management and cancer therapy. Overall, the investigation of GNPDA1 not only enhances our comprehension of metabolic processes but also holds considerable potential for advancing medical science.
